Systems and methods for controlling photoactivatable drugs - Patents.com

The system uses light modulators to control photoactivatable agents with spatial and temporal precision, addressing the issue of systemic drug delivery's side effects by activating or inactivating agents at specific body locations and times, thus improving treatment efficacy.

JP2024540963AActive Publication Date: 2024-11-06ELI LILLY & CO
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024523769
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-21
Filing Date
2022-10-14
Publication Date
2024-11-06
Estimated Expiration
2042-10-14

AI Technical Summary

Technical Problem

Existing treatments for localized medical conditions, such as certain cancers and skin conditions, often require systemic drug delivery, which can adversely affect healthy tissues due to the impracticality and ineffectiveness of localized administration.

Method used

A system and method using light modulators to control photoactivatable agents within the body by emitting specific wavelengths of light to activate or inactivate these agents, allowing for spatial and temporal control through closed-loop feedback mechanisms.

Benefits of technology

Enables precise activation and deactivation of photoactivatable agents at targeted locations and times, minimizing impact on healthy tissues and enhancing treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540963000001_ABST
    Figure 2024540963000001_ABST
Patent Text Reader

Abstract

A system for controlling a photoactivatable agent in a subject includes a light modulator and a controller. The light modulator is operable to emit light at a first wavelength and light at a second wavelength. The light at the first wavelength is configured to activate the photoactivatable agent and the light at the second wavelength is configured to deactivate the photoactivatable agent. The controller is operably coupled to the light modulator. The controller is operable to cause the light modulator to (1) emit light at the first wavelength, thereby activating the photoactivatable agent, and (2) emit light at the second wavelength, thereby deactivating the photoactivatable agent.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THE DISCLOSURE The present disclosure relates to systems and methods for activating and deactivating drugs within a subject's body, and more particularly, to light modulator systems and methods for controlling light activatable drugs within a subject's body. [Background technology]

[0002] Treatment of various localized medical conditions, such as some forms of cancer and some skin conditions, typically involves delivering one or more drugs to a subject generally (i.e., non-locally). Such treatments are typically used because it is impractical and / or ineffective to deliver one or more drugs locally. Such drugs, while effectively treating diseased tissue, often also adversely affect healthy tissue. Thus, there is a need for improved systems and methods for delivering treatment via drugs. Summary of the Invention

[0003] The present disclosure provides light modulator systems and methods for controlling one or more light activatable agents within a subject's body.

[0004] According to one embodiment of the present disclosure, a system for controlling a photoactivatable agent in a subject includes a light modulator and a controller. The light modulator is operable to emit light at a first wavelength and light at a second wavelength. The light at the first wavelength is configured to activate the photoactivatable agent, and the light at the second wavelength is configured to deactivate the photoactivatable agent. The controller is operatively coupled to the light modulator, the controller is operable to cause the light modulator to (1) emit light at the first wavelength, thereby activating the photoactivatable agent, and (2) emit light at the second wavelength, thereby deactivating the photoactivatable agent.

[0005] In some embodiments, activation is modulated by physiological events (which may also be referred to as the "outer closed loop"). In some embodiments, activation is modulated by measured levels of active compound in the body (which may also be referred to as the "inner closed loop").

[0006] In some embodiments, the light modulator includes a first emitter configured to emit light at a first wavelength and a second emitter configured to emit light at a second wavelength.

[0007] In some embodiments, the optical modulator includes a plurality of first emitters configured to emit light at a first wavelength and a plurality of second emitters configured to emit light at a second wavelength.

[0008] In some embodiments, the plurality of second emitters are arranged to define at least a portion of a perimeter, and the plurality of first emitters are disposed within the portion of the perimeter.

[0009] In some embodiments, the system further includes a wearable device configured to be secured to the skin of the subject, the wearable device including the light modulator.

[0010] In some embodiments, the wearable device includes a controller.

[0011] In some embodiments, the system further includes an implantable device configured to be disposed within a body of a subject, the implantable device including the light modulator.

[0012] In some embodiments, the implantable device includes a controller.

[0013] In some embodiments, the system further includes an implantable device having the light modulator and configured to be disposed within a body of a subject. The implantable device includes an activation probe and a passivation cuff. The activation probe is configured to be disposed within a target mass of the subject, the activation probe including a first emitter configured to emit light at a first wavelength. The passivation cuff is configured to be secured to a blood vessel coupled to the target mass of the subject, the passivation cuff including a second emitter configured to emit light at a second wavelength.

[0014] In some embodiments, the system further includes an optical element coupled to the light modulator.

[0015] In some embodiments, the optical element is a microlens array.

[0016] In some embodiments, the microlens array includes an electrochromic coating.

[0017] In some embodiments, the optical element is a diffractive optical element.

[0018] In some embodiments, the controller is operable to cause the light modulator to emit light at the first wavelength and light at the second wavelength simultaneously.

[0019] According to another embodiment of the present disclosure, a system for controlling a photoactivatable agent in a subject includes a light modulator, an activation sensor, and a controller. The light modulator is operable to emit light, where the light is configured to activate the photoactivatable agent. The activation sensor (which may be part of an "inner closed loop, for example) is operable to determine an amount of activated photoactivatable agent in the subject. The controller is operably coupled to the light modulator and the activation sensor. The controller is operable to cause the light modulator to emit light, thereby activating the photoactivatable agent, and to modify the amount of light emitted by the light modulator in response to the amount of activated photoactivatable agent in the subject determined by the activation sensor.

[0020] According to another embodiment of the present disclosure, a system for controlling a photoactivatable agent in a subject includes a light modulator, an activation sensor, and a controller. The light modulator is operable to emit light, the light configured to activate the photoactivatable agent. The activation sensor (which may be part of an "outer closed loop, for example) is operable to determine a physiological event that warrants activation of the agent in the subject. The controller is operably coupled to the light modulator and the activation sensor. The controller is operable to cause the light modulator to emit light, thereby activating the photoactivatable agent, and to modify the amount of light emitted by the light modulator in response to changes in the patient's physiological condition.

[0021] According to another embodiment, both the inner closed loop and the outer closed loop are implemented in the same system or device.

[0022] In some embodiments, the activation sensor includes an excitation emitter, a fluorophore, and a fluorescence detector. The excitation emitter is operable to emit light at a first wavelength. The fluorophore is configured to emit light at a second wavelength upon receiving light at the first wavelength when the fluorophore is in the presence of an activated photoactivatable agent. The fluorescence detector is operable to detect the light at the second wavelength emitted by the fluorophore.

[0023] In some embodiments, the activated sensor further comprises a waveguide that optically couples the excitation emitter to the fluorophore.

[0024] In some embodiments, the waveguide comprises an optical fiber.

[0025] In some embodiments, the fluorescence detector comprises a photodiode.

[0026] In some embodiments, the excitation emitter comprises a light emitting diode.

[0027] In some embodiments, the system further includes an excitation filter that optically couples the excitation emitter to the fluorophore.

[0028] In some embodiments, the system further comprises an emission filter that optically couples the fluorophore to the fluorescence detector.

[0029] In some embodiments, the activated sensor includes a chemical sensor.

[0030] In some embodiments, the activated sensor includes multiple chemical sensors.

[0031] In some embodiments, the activated sensor further comprises an excitation emitter operable to emit light at a first wavelength, and the plurality of chemical sensors each comprise a fluorophore configured to emit light at a second wavelength upon receiving light at the first wavelength when in the presence of a photoactivatable agent that has been activated by the fluorophore, and the activated sensor further comprises a fluorescence detector operable to detect light at the second wavelength emitted by the fluorophore.

[0032] In some embodiments, the activated sensor further comprises a plurality of ring resonators operable to filter the light of the second wavelength emitted by the phosphor.

[0033] In some embodiments, the activated sensor further comprises a waveguide that optically couples the excitation emitter to the multiple chemical sensors.

[0034] In some embodiments, the activated sensor further comprises a waveguide that optically couples the plurality of chemical sensors to the fluorescence detector.

[0035] In some embodiments, the waveguide comprises an optical fiber.

[0036] In some embodiments, the activation sensor is a first activation sensor, and the system further includes a second activation sensor operable to determine a physiological event in the subject, and the controller is further operable to modify the amount of light emitted by the light modulator in response to the second activation sensor determining a physiological event in the subject. [Brief description of the drawings]

[0037] The above and other advantages and objects of the present invention, and the manner in which they are accomplished, will become more apparent, and the invention itself will be better understood, by reference to the following description of an embodiment of the invention taken in conjunction with the accompanying drawings, in which: [Figure 1] FIG. 1 is a schematic diagram of a system for controlling a photoactivatable agent in a subject, according to one embodiment of the present disclosure. [Diagram 2] FIG. 13 is a schematic diagram of a wearable device for controlling a photoactivatable drug in a subject, according to another embodiment of the present disclosure. [Diagram 3] FIG. 3 is an exploded perspective view of the wearable device of FIG. 2. [Figure 4] FIG. 13 is a schematic diagram of a wearable device for controlling a photoactivatable drug in a subject, according to another embodiment of the present disclosure. [Diagram 5] FIG. 5 is an exploded perspective view of the wearable device of FIG. [Figure 6] FIG. 2 is a top view of an exemplary diffractive optical element for a device for controlling a photoactivatable agent in a subject, according to an embodiment of the present disclosure. [Figure 7] 7 is an enlarged top view of a portion of the diffractive optical element of FIG. 6. [Figure 8] FIG. 13 is a top view of another exemplary diffractive optical element for a device for controlling a photoactivatable agent in a subject, according to an embodiment of the present disclosure. [Figure 9] FIG. 9 is an enlarged perspective view of a portion of the diffractive optical element of FIG. 8. [Figure 10] FIG. 13 is a top view of yet another exemplary diffractive optical element for a device for controlling a photoactivatable agent in a subject, according to an embodiment of the present disclosure. [Figure 11] FIG. 13 is a perspective view of yet another exemplary diffractive optical element for a device for controlling a photoactivatable agent in a subject, according to an embodiment of the present disclosure. [Figure 12] FIG. 2 is a side view of an exemplary microlens array for a device for controlling a photoactivatable agent in a subject, according to an embodiment of the present disclosure. [Figure 13] FIG. 2 is a top view of a wearable device for controlling a photoactivatable drug in a subject according to another embodiment of the present disclosure. [Figure 14] FIG. 14 is a side view of the wearable device of FIG. 13. [Figure 15] FIG. 1 is a schematic diagram of an implantable device for controlling a photoactivatable agent in a subject, according to another embodiment of the present disclosure. [Figure 16] FIG. 13 is a schematic diagram of a wearable device for controlling a photoactivatable drug in a subject, according to another embodiment of the present disclosure. [Figure 17] FIG. 17 is an enlarged perspective view of the implantable device of FIG. 16. [Figure 18] FIG. 1 is a schematic diagram of a sensor for sensing an activated photoactivatable agent in a subject, according to one embodiment of the present disclosure. [Figure 19] FIG. 19 is a schematic diagram of an electronics assembly for use with the sensor of FIG. 18. [Figure 20] FIG. 13 is a perspective cross-sectional view of a sensor for sensing an activated photoactivatable agent in a subject according to another embodiment of the present disclosure. [Figure 21] FIG. 13 is a schematic diagram of a sensor for sensing an activated photoactivatable agent in a subject, according to another embodiment of the present disclosure. [Figure 22] 22 is a graph illustrating the chemical sensor spectrum of the sensor of FIG. 21. [Figure 23] 22 is a graph illustrating the spectra of the treatment region ring resonator and the boundary ring resonator of the sensor of FIG. 21 . [Figure 24] 22 is a graph illustrating the spectrum of fluorescent light transmitted to the waveguide of the sensor of FIG. 21.

[0038] Corresponding reference characters indicate corresponding parts throughout the several views. Although the drawings represent embodiments of the present invention, the drawings are not necessarily to scale and certain features may be exaggerated or omitted in some of the drawings in order to better illustrate and explain the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] Systems and methods according to embodiments of the present disclosure facilitate controlling one or more photoactivatable agents, which may also be referred to as photoactivatable medicines or drugs. Generally, a photoactivatable agent may be configured or activated to an active state by exposure to one or more wavelengths of light. In the active state, the photoactivatable agent is configured to cause one or more pharmacological effects on the subject's body. Stated differently, in the active state, the photoactivatable agent is configured to provide a pharmacological treatment to the subject. A photoactivatable agent may also be configured or inactivated to an inactive state by exposure to one or more different wavelengths of light. In the inactive state, the photoactivatable agent does not cause a pharmacological effect on the subject's body. Stated differently, in the inactive state, the photoactivatable agent is inactive to the subject's body.

[0040] The photoactivatable drug may include, for example, photocaged raceglurant, more specifically as described by J. Font et al., "Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator", eLife, vol. 6, p. e23545, Apr. 2017, doi: 10.7554 / eLife.23545, or photocaged morphine, more specifically as described by M. Lopez-Cano et al., "Remote local photoactivation of morphine produces analgesia without opioid-related adverse effects", British Journal of Pharmacology, p. bph. 15645, Sep. 2021, doi: 10.1111 / bph.15645. Both of the above publications are incorporated herein by reference.

[0041] The photoactivatable agent may be initially administered to the subject, for example, in liquid form and / or via a syringe assembly or intravenous ("intravenous (IV") tubing. The photoactivatable agent may then be distributed within the subject's body via the circulatory system.

[0042] Systems and methods according to embodiments of the present disclosure facilitate activating and deactivating photoactivatable agents at different body locations and / or at specific times, or stated another way, systems and methods according to embodiments of the present disclosure facilitate control of photoactivatable agents with spatial / temporal specificity.

[0043] Systems according to embodiments of the present disclosure are operated by a user (e.g., a medical professional, caregiver, or another person) in a manner generally described herein to control one or more light-activatable agents in a subject (e.g., another person or user).

[0044] 1 generally illustrates a system 100 for controlling one or more photoactivatable agents in a subject, according to one embodiment of the present disclosure. Generally, the system 100 includes a control module 102 operably coupled to one or more light modulators 104 (illustratively, via wireless communication; as used in this application, the term "operably coupled" includes wired and wireless data communication, whether direct or indirect via one or more intervening devices or components, and such data communication may be continuous or intermittent). The control module 102 is operable to cause the light modulators 104 to (1) emit one or more wavelengths of light that activate the photoactivatable agents, and (2) emit one or more different wavelengths of light that deactivate the photoactivatable agents. These aspects are described in more detail below.

[0045] 1, the control module 102 includes one or more controllers 106, which may be any device or component capable of executing stored software and / or firmware code that, when executed by the controllers 106, causes the system 100 to perform the functions described herein. The controllers 106 may be, for example, an application-specific integrated circuit (ASIC), a field-programmable gate array (FPGA), a digital signal processor (DSP), hardwired logic, combinations thereof, etc.

[0046] Controller 106 is operatively coupled (illustratively via wired communication) to memory 108 for storing, for example, software or firmware code or sensed parameters, as described in further detail below. Memory 108 may be any suitable computer-readable medium accessible by processor 106. Memory 108 may be a single storage device or multiple storage devices, may be located internal or external to controller 106, and may include both volatile and non-volatile media. Memory 108 may be, for example, random-access memory (RAM), read-only memory (ROM), electrically erasable programmable ROM (EEPROM), flash memory, magnetic storage device, optical disk storage, or any other suitable medium capable of storing data and accessible by controller 106.

[0047] Controller 106 is also operatively coupled (illustratively via wired communication) to a power source 110 for providing power to various components of system 100. Power source 110 may be, for example, one or more rechargeable batteries, one or more inductive / wireless power receivers, etc.

[0048] The controller 106 is further operatively coupled (illustratively, via wired communication) to a transmitter 112 for wirelessly transmitting information, such as sensed parameters (e.g., which may be sensed as part of the “outer closed loop”), to one or more remote devices (not shown), such as a mobile device, including a smartphone, smartwatch, or tablet device, a personal computer, a remote computer, or a database. The transmitter 112 may be, for example, a Bluetooth transmitter, an IEEE 802.11 transmitter, a cellular communication transmitter, a short-range communication transmitter, or the like. The transmitter 112 may be continuously or intermittently coupled to the remote device. A transceiver (not shown) may be used in place of the transmitter 112 to facilitate the provision of information from the remote device to the system 100. Such information may include, for example, software updates.

[0049] Continuing to refer to FIG. 1 , the light modulator 104 includes one or more first emitters 114 and one or more second emitters 116. The first emitters 114 emit light at a first wavelength that activates the photoactivatable agent. More specifically, the first emitters 114 may be configured to emit light having a wavelength of about 450 nm, for example, or blue light. Illustratively, the first emitters 114 may emit only light at the first wavelength. Alternatively, the first emitters 114 may be capable of emitting light at multiple wavelengths, and the controller 106 may cause the first emitters 114 to emit light at the first wavelength. The first emitters 114 may be light-emitting diodes ("LEDs"), or the like. Similarly, the second emitters 116 emit light at a second wavelength that deactivates the photoactivatable agent. More specifically, the second emitter 116 may be configured to emit light having a wavelength of about 550 nm, for example, or green light. Illustratively, the second emitter 116 may emit only light at the second wavelength. Alternatively, the second emitter 116 may be capable of emitting light at multiple wavelengths, and the controller 106 may cause the second emitter 116 to emit light at the second wavelength. The second emitter 116 may be an LED, or the like.

[0050] Alternatively, instead of including a first emitter 114 and a second emitter 116 as described above, the light modulator 104 may include one or more emitters configured to emit light at a first wavelength (e.g., at particular times and / or based on sensed parameters) and light at a second wavelength (e.g., at other times and / or based on other sensed parameters).

[0051] With further reference to FIG. 1 , the light modulator 104 also includes one or more sensors 118. The sensors 118 may sense physiological parameters and / or parameters related to the light activatable agent. The physiological parameters may include, for example, physiological parameters indicative of pain experienced by the subject, physiological parameters indicative of inflammation (such as cytokine levels), temperature of the subject and / or body part of the subject, physiological parameters indicative of a diabetic event (such as changes in glucose levels), changes in heart rate, and characteristics of the target mass (e.g., diseased tissue). The parameters related to the light activatable agent may include, for example, the presence or amount of an inactivated light activatable agent and / or the presence or amount of an activated light activatable agent. As described in more detail below, the controller 106 may modify the operation of the system 100, and more specifically, the amount of light emitted by the light modulator 104, based on the parameters sensed by the sensors 118.

[0052] The system according to the present disclosure may be incorporated into a device configured to be worn by a subject, or a wearable device. Referring now to FIG. 2 and FIG. 3, a wearable device 200 according to an embodiment of the present disclosure is illustrated. The wearable device 200 is a more specific embodiment of the system 100 described above. As such, the wearable device 200 includes some of the same components and operates in a similar manner as the system 100 described above. Generally, the wearable device 200 is configured in the form of a patch. More specifically, the wearable device 200 includes a flexible base or housing 202 configured to be removably secured to the skin of a subject (e.g., via one or more adhesives (not shown)). The subject-facing side 204 of the base 202 is configured to be secured to the skin of the subject. The opposing surface 206 of the base 202 carries an optical element 208 (FIG. 3), an optical modulator 210 (FIG. 3), a control module 212 (FIG. 3), and a flexible cover 214 for securing these components to the base 202. The base 202 may further include a transparent portion 216 (FIG. 3) adjacent the optical element 208 and the light modulator 210 to facilitate emission of light from the wearable device 200.

[0053] 3, the control module 212 may be the same as or similar to the control module 102 described above. Similarly, the light modulator 210 may be the same as or similar to the light modulator 104 described above. More specifically, the light modulator 210 includes one or more first emitters 218 configured to emit light at a first wavelength and one or more second emitters 220 configured to emit light at a second wavelength. The light modulator 210 also includes a number of sensors 222. The optical element 208 is configured to receive light from the first emitters 218 and the second emitters 220 and direct the light more uniformly towards the target. The optical element 208 may take a variety of forms, and exemplary details are described below.

[0054] Continuing to refer to FIG. 3, the first emitter 218 and the second emitter 220 are arranged in a grid, more specifically, in a grid of three rows and three columns. Illustratively, the first emitter 218 is disposed at the center of the grid, and the second emitter 220 forms the periphery of the grid. Thus, the wearable device 200 may be positioned such that the first emitter 218 is adjacent to a target mass (e.g., diseased tissue) of a subject. The first emitter 218 may emit light at a first wavelength to activate a photoactivatable agent in the target mass, and the second emitter 220 may simultaneously emit light at a second wavelength to inactivate the photoactivatable agent as it circulates away from the target mass. In other embodiments, the first emitter 218 and the second emitter 220 may have different arrangements.

[0055] 4 and 5, a wearable device 300 according to one embodiment of the present disclosure is illustrated. The wearable device 300 is similar to the wearable device 200 described above. More specifically, the wearable device 300 includes a base (not shown) carrying an optical element 302, a light modulator 304, a control module (not shown), and a cover 306 for fixing these components to the base. With particular reference to FIG. 5, the first emitter 308 and the second emitter 310 of the light modulator 304 are generally arranged in the shape of a plus sign (i.e., "+"). Illustratively, the first emitter 308 is disposed on the side of the symbol, and the second emitter 310 forms the periphery of the symbol. Thus, the wearable device 300 can be positioned such that the first emitter 308 is adjacent to a target mass of a subject. The first emitter 308 may emit light at a first wavelength to activate a photoactivatable agent within the target mass, and the second emitter 310 may simultaneously emit light at a second wavelength to deactivate the photoactivatable agent as it circulates away from the target mass.

[0056] As briefly discussed above, devices according to the present disclosure may include optical elements for directing light to a target. Such optical elements may take a variety of forms. For example, optical elements may include lenses or diffractive optical elements, elements including a pattern of opaque and transparent portions. FIGS. 6 and 7 illustrate an exemplary diffractive optical element 400. The diffractive optical element 400 includes a grid of circular zone plates 402 (three of which are identified in FIG. 6), each of which includes alternating and concentric opaque rings 404 and transparent rings 406 (two of each are identified in FIG. 7). Illustratively, the rings 404, 406 decrease in thickness as they move away from the center of each circular zone plate 402. The thickness of the rings 404, 406 may also be adjusted to create a desired optical wavefront at the target mass through diffraction. Factors such as the location of the light source, the location of the target mass, and the wavelength of the light to be diffracted will affect the final thickness selected for the zone plate rings. Circular zone plate 402 may be provided in different sizes, and FIG. 6 illustrates two such sizes.

[0057] 8 and 9 illustrate another exemplary diffractive optical element 500. Diffractive optical element 500 includes a grid of hexagons 502 (three of which are identified in FIG. 8), with each hexagon 502 including alternating and concentric opaque rings 504 and semi-transparent rings 506 (two of each are identified in FIG. 9). Illustratively, the rings 504, 506 are truncated near the edges of each hexagon 502, and the rings 504, 506 decrease in thickness moving away from the center of each hexagon 502.

[0058] FIG. 10 illustrates another exemplary diffractive optical element 600. The diffractive optical element 600 includes a grid of circles 602 (two of which are identified in FIG. 10), each circle 602 including alternating and concentric opaque rings 604 and semi-transparent rings 606 (two of each are identified in FIG. 10). Illustratively, the rings 604, 606 decrease in thickness as they move away from the center of each circle 602. The diffractive optical element 600 also includes approximate triangles 608 between adjacent circles 602 (two of which are identified in FIG. 10). Each triangle 608 includes alternating and concentric opaque triangles 610 and semi-transparent triangles 612 (two of each are identified in FIG. 10). Illustratively, the triangles 610, 612 decrease in thickness as they move away from the center of each triangle 608.

[0059] 11 illustrates yet another exemplary diffractive optical element 700. Diffractive optical element 700 includes a grid of hexagons 702 (two of which are identified in FIG. 11), with each hexagon 702 including alternating and concentric opaque hexagons 704 and semi-transparent hexagons 706 (two of each are identified in FIG. 11). Illustratively, the hexagons 704, 706 decrease in thickness with distance from the center of each hexagon 702.

[0060] As another example, the optical element may be a microlens array, or an array including a plurality of relatively small lenses. Such an array may direct light more uniformly toward the subject and may be relatively compact compared to a standard lens. FIG. 12 provides a profile view (i.e., a view from the side) of an exemplary microlens array 800. The array 800 includes a plurality of relatively small lenses 802, which may be arranged in a grid. More specifically, the lenses 802 may be arranged horizontally as illustrated and extend into the page. The microlens array 800 may be constructed from one or more flexible biocompatible materials. The lenses 802 may have an electrochromic coating (not shown), and each lens 802 may be controlled in a manner similar to a pixel. As a result, the microlens array 800 may facilitate emitting light of a first wavelength and / or light of a second wavelength to a relatively small area of ​​the subject's body.

[0061] A wearable device according to the present disclosure may be modified in various other ways. For example, one or more components of the system 100 may be disposed remotely from a wearable device according to the present disclosure. As a more specific example, FIG. 13 and FIG. 14 illustrate a wearable device 900 according to which another embodiment of the present disclosure is illustrated. The wearable device 900 is similar to the wearable device described above. More specifically, the wearable device 900 includes a housing 902 carrying a flexible substrate 904, which carries a light modulator 906. The light modulator 906 includes one or more first emitters 908 and one or more second emitters 910. The flexible substrate 904 also carries a sensor 912. The light modulator 906 and the sensor 912 are operably coupled to a control module (not shown) via wired communication. Alternatively, the light modulator 906 and the sensor 912 are operatively coupled to the control module via wireless communication, which may be part of a separate wearable device (not shown) or a non-wearable device (not shown).

[0062] The system according to the present disclosure may be incorporated into a device configured to be implanted in a subject, or into an implantable device. Referring now to FIG. 15, an implantable device 1000 according to an embodiment of the present disclosure is illustrated. The implantable device 1000 is a more specific embodiment of the system 100 described above. Thus, the implantable device 1000 includes some of the same components and operates in the same manner as the system 100 described above. Generally, the implantable device 1000 includes a housing 1002 configured to be implanted in a subject. The housing 1002 carries a control module 1004, which is operably coupled to a light modulator 1006 via wired communication. The control module 1004 may be the same as or similar to the control module 102 described above. The light modulator 1006 includes an activation probe 1008 configured to be disposed in the target mass TM. The probe 1008 has one or more first emitters 1010 configured to emit light of a first wavelength into the target tissue TM. The light modulator 1006 also includes a number of inactivation cuffs 1012 configured to extend around or otherwise be secured to a blood vessel BV coupled to the target mass TM. Each cuff 1012 includes one or more second emitters 1014 configured to emit light at a second wavelength. Thus, the first emitter 1010 may emit light at a first wavelength to activate a photoactivatable agent in the target mass TM, and the second emitter 1014 may emit a second wavelength to inactivate the photoactivatable agent as it travels through the blood vessel BV away from the target mass TM.

[0063] 16 and 17, an implantable device 1100 according to an embodiment of the present disclosure is illustrated. The implantable device 1100 is a more specific embodiment of the system 100 described above. Thus, the implantable device 1100 includes some of the same components and operates in the same manner as the system 100 described above. Generally, the implantable device 1100 is constructed in the form of a capsule, and the implantable device 1100 can be implanted percutaneously via an introducer I. More specifically, the implantable device 1100 includes a housing 1102 configured to be implanted in a subject. The housing 1102 carries an optical modulator 1104 and a control module 1106 (FIG. 17). The control module 1106 may be the same as or similar to the control module 102. Similarly, the optical modulator 1104 may be the same as or similar to the optical modulator 104 described above. More specifically, the light modulator 1104 includes one or more first emitters 1108 configured to emit light at a first wavelength and one or more second emitters 1110 configured to emit light at a second wavelength. The first emitters 1108 and the second emitters 1110 may emit light at the same or different times, or the implantable device 1100 may emit light at a first wavelength and a second similar implantable device (not shown) may emit light at a second wavelength. Alternatively, in some embodiments, the first emitters 1108 and the second emitters 1110 may be the same type of emitter and collectively configured to emit light at a first wavelength at a first time and light at a second different time. In some embodiments, the implantable device 1100 includes one or more sensors (such as sensor 118 shown elsewhere) for sensing a physiological parameter and / or a parameter related to a photoactivatable agent. The sensors may be disposed adjacent to the first emitter 1108 and the second emitter 1110 or elsewhere on or within the implantable device 1100.

[0064] As briefly described above, the operation of the system 100 may be modified based on parameters sensed by the sensor 118. More specifically, the system 100 may modify the amount of light emitted by the light modulator 104 based on parameters sensed by the sensor 118. Modifying the amount of light emitted by the light modulator 104 may include, for example, modifying the intensity of the light emitted, modifying the duration of the emission of the light, modifying the pattern of the emission of the light (e.g., varying the timing at which light is emitted and not omitted), modifying the size of the area from which the light is emitted (even if the intensity per unit area remains constant).

[0065] The sensor 118 may take various forms. For example, one or more sensors 118 may sense a parameter related to the photoactivatable agent. FIG. 18 illustrates an exemplary actuation sensor 1200 for sensing such a parameter. More specifically, the activation sensor 1200 is configured to sense the presence and amount of an activated photoactivatable agent in a subject. The sensor 1200 is configured to be disposed internally relative to the subject. In general, the sensor 1200 includes a waveguide 1202, such as an optical fiber, for transmitting light EL of a first wavelength (which may be referred to as "excitation light" and has a wavelength of, for example, about 475 nm) to a phosphor 1204. Upon receiving light EL of the first wavelength, the phosphor 1204 emits light FL of a second wavelength (which may be referred to as "fluorescence" and has a wavelength of, for example, about 515 nm) in the presence of an activated photoactivatable agent AA (determined based on the activated agent itself or a biomarker indicative of an activated substance such as calcium ions). The phosphor 1204 emits an amount of light FL at the second wavelength that corresponds to the current amount of activated photoactivatable agent AA. The waveguide 1202 transmits the light FL at the second wavelength emitted by the phosphor 1204 back to a sensor that detects and / or measures the amount of light FL at the second wavelength, and the system 100 may modify the amount of light emitted by the light modulator 104 (FIG. 1) based on the amount of light FL at the second wavelength transmitted by the waveguide 1202.

[0066] FIG. 19 illustrates generally an exemplary electronics assembly 1300 for use with the actuation sensor 1200 (FIG. 18). The electronics assembly 1300 includes a power source or power supply 1302 for providing power to various components of the electronics assembly 1300. The power supply 1302 may be, for example, the same power supply 110 as described above, or may be a different device. The power supply 1302 is operably coupled (illustratively, via wired communication) to a power regulator 1304 including one or more low dropout regulators (not shown). The power regulator 1304 is operably coupled (illustratively, via wired communication) to one or more amplifiers and filters 1306, a controller or microcontroller 1310, and a constant current driver 1311. The amplifiers and filters 1306 are operably coupled (illustratively, via wired communication) to a fluorescence detector or light sensor 1308. The controller 1310 may be, for example, the same as the controller 106 described above, or may be a different device. The controller 1310 is operatively coupled (illustratively, via wired communication) to the amplifier and filter 1306 via an analog-to-digital converter 1312. The controller 1310 is also operatively coupled (illustratively, via wired communication) to a transmitter or antenna 1314 via a radio 1315. The controller 1310 is also operatively coupled (illustratively, via wired communication) to a constant current driver 1311 via a digital-to-analog converter 1316. The constant current source converter 1311 is operatively coupled (illustratively, via wired communication) to an excitation emitter or light source 1318. The excitation emitter 1318 emits excitation light into the waveguide 1202 of the sensor 1200 ( FIG. 18 ), which transmits the fluorescent light to the fluorescent light detector 1308. The controller 1310 detects the fluorescence received by the fluorescence detector 1308 to determine the presence and amount of activated photoactivatable agent within the subject, whereby the system 100 can modify the amount of light emitted by the light modulator 104 (FIG. 1).

[0067] 20, a sensor 1400 according to an embodiment of the present disclosure is illustrated. The sensor 1400 is a more specific embodiment of the sensor 1200 described above. Thus, the sensor 1400 includes some of the same components and operates in the same manner as the sensor 1200 described above. The sensor 1400 may also be used with the electronics assembly 1300 (FIG. 19). The sensor 1400 includes a housing 1402 that carries various components, including the excitation emitter 1318 of the electronics assembly 1300. The excitation emitter 1318 transmits excitation light to the waveguide 1202 (FIG. 18) via a first lens 1404, an excitation filter 1406, a beam splitter 1408, and a second lens 1410. The waveguide 1202 is carried by a mechanical coupler 1411. The waveguide 1202 transmits the excitation light to an optrode 1412 that includes a fluorophore 1204 (FIG. 18). As described above, upon receiving the excitation light, in the presence of an activated photoactivatable agent, the fluorophore 1204 emits fluorescent light into the waveguide 1202. The waveguide 1202 transmits the fluorescent light to the fluorescence detector 1308 via a second lens 1410, a beam splitter 1408, and an emission filter 1414. The controller 1310 (FIG. 19) detects the fluorescence received by the fluorescence detector 1308 to determine the presence and amount of an activated photoactivatable agent in the subject, whereby the system 100 may modify the amount of light emitted by the light modulator 104 (FIG. 1).

[0068] FIG. 21 illustrates in schematic form another exemplary activation sensor 1500 for sensing a parameter related to a photoactivatable agent. The activation sensor 1500 may be used in place of or in addition to the sensor 1200 (FIG. 18). The activation sensor 1500 is configured to sense the presence, amount, and location of an activated photoactivatable agent in a subject. The sensor 1500 is configured to be disposed internally relative to the subject. In general, the sensor 1500 includes a first waveguide 1502, such as an optical fiber, for transmitting excitation light EL to one or more chemical sensors 1504 (two of which are identified). Each chemical sensor 1504 includes a fluorophore 1506 that emits fluorescence in the presence of an activated photoactivatable agent AA (determined based on the activated agent itself or a biomarker indicative of the activated substance, such as calcium ions) upon receiving the excitation light EL. Each fluorophore 1506 emits an amount of fluorescence corresponding to an adjacent amount of activated photoactivatable agent AA. That is, the fluorophores 1506 are configured to independently emit different amounts of fluorescent light. The fluorescent light emitted by the fluorophores 1506 is filtered by a number of ring resonators 1508 (two of which are identified). The ring resonators 1508 drawn in dashed lines depict "treatment area" ring resonators configured to be disposed adjacent to a target treatment area of ​​a subject, while the ring resonators 1508 drawn in solid lines depict "boundary" ring resonators configured to be disposed along a boundary or perimeter of the target treatment area. Each ring resonator filters the light emitted by the fluorophores 1506 to pass light having certain frequencies and reject light having other frequencies. The filtered fluorescent light is received by a second waveguide 1510, such as an optical fiber. The second waveguide 1510 transmits the filtered fluorescent light FL, and the system 100 may modify the amount of light emitted by the light modulator 104 (FIG. 1) based on the amount of fluorescent light FL and / or location information encoded within the fluorescent light FL.

[0069] FIG. 22 illustrates the spectrum of the chemical sensor 1504 (FIG. 21). As can be seen, each chemical sensor emits multiple frequencies of light. FIG. 23 illustrates the transmission spectrum (i.e., the amount of light transmitted and not filtered out) of the "treatment zone" ring resonator 1508 (FIG. 21, i.e., the ring resonator 1508 drawn in phantom) and the "boundary" ring resonator 1508 (i.e., the ring resonator 1508 drawn in solid). FIG. 24 illustrates the spectrum of the fluorescence from the chemical sensor 1504 after it has been filtered through the ring resonator 1508 and sent to the second waveguide 1510 (FIG. 21). As seen in FIG. 24, the filtered light may be expected to occupy two frequency regions, a first frequency region including light filtered through the “treatment region” ring resonator 1508, and a second frequency region including light filtered through the “boundary” ring resonator 1508; in this embodiment, the first frequency region is lower in frequency than the second frequency region, but the activated sensor 1500 may alternatively be configured such that the first frequency region is higher in frequency than the second frequency region. By measuring the intensity of the filtered light transmitted to the second waveguide 1510 in each of these different frequency regions, the measurement system may separately determine (i) the amount of light emitted by the chemical sensor adjacent to the treatment region, and (ii) the amount of light emitted by the chemical sensor disposed along the boundary or perimeter of the target treatment region. In this manner, the measurement system may separately determine the amount of activated photoactivatable agent AA in the treatment region and the boundary region.

[0070] While this invention has been shown and described as having a preferred design, the invention may be modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations of the invention using its general principles. Further, this application is intended to cover such departures from the disclosure as come within known or customary practice in the art to which this invention pertains.

Claims

1. 1. A system for controlling a photoactivatable agent in a subject, comprising: a light modulator operable to emit light at a first wavelength and light at a second wavelength, the light at the first wavelength configured to activate the photoactivatable drug and the light at the second wavelength configured to deactivate the photoactivatable drug; a controller operably coupled to the light modulator; The system, wherein the controller is operable to cause the light modulator to (1) emit light at the first wavelength, thereby activating the photoactivatable drug, and (2) emit light at the second wavelength, thereby deactivating the photoactivatable drug.

2. 10. The system of claim 1, wherein the optical modulator comprises a first emitter configured to emit light at the first wavelength and a second emitter configured to emit light at the second wavelength.

3. 10. The system of claim 1 , wherein the optical modulator comprises a plurality of first emitters configured to emit light at the first wavelength and a plurality of second emitters configured to emit light at the second wavelength.

4. The system of claim 3 , wherein the plurality of second emitters are arranged to define at least a portion of a perimeter, and the plurality of first emitters are disposed within the portion of the perimeter.

5. The system of claim 1 , further comprising a wearable device configured to be secured to the skin of the subject, the wearable device including the light modulator.

6. The system of claim 5 , wherein the wearable device includes the controller.

7. The system of any one of claims 1 to 4, further comprising an implantable device configured to be disposed within the subject's body, the implantable device comprising the optical modulator.

8. The system of claim 7 , wherein the implantable device includes the controller.

9. and an implantable device configured to be disposed within a body of the subject, the implantable device including the optical modulator, the implantable device comprising: an activation probe configured to be disposed within a target mass of the subject, the activation probe comprising a first emitter configured to emit light at the first wavelength; 2. The system of claim 1, comprising: a deactivation cuff configured to be secured to a blood vessel coupled to the target mass of the subject, the deactivation cuff comprising a second emitter configured to emit light at the second wavelength.

10. The system of any one of claims 1 to 9, further comprising an optical element coupled to the light modulator.

11. The system of claim 10 , wherein the optical element is a microlens array.

12. The system of claim 11 , wherein the microlens array comprises an electrochromic coating.

13. The system of claim 10 , wherein the optical element is a diffractive optical element.

14. A system according to any preceding claim, wherein the controller is operable to cause the light modulator to emit light at the first wavelength and light at the second wavelength simultaneously.

15. 1. A system for controlling a photoactivatable agent in a subject, comprising: a light modulator operable to emit light, the light configured to activate the photoactivatable agent; an activation sensor operable to determine an amount of the photoactivatable agent activated in the subject; a controller operably coupled to the light modulator and the activation sensor; The system, wherein the controller is operable to cause the light modulator to emit the light, thereby activating the photoactivatable drug, and to modify the amount of light emitted by the light modulator in response to an amount of activated photoactivatable drug in the subject determined by the activation sensor.

16. The activation sensor comprises: an excitation emitter operable to emit light at a first wavelength; a fluorophore configured to emit light at a second wavelength upon receiving light at the first wavelength when the fluorophore is in the presence of an activated photoactivatable agent; and a fluorescence detector operable to detect light at the second wavelength emitted by the fluorophore.

17. 17. The system of claim 16, wherein the activated sensor further comprises a waveguide optically coupling the excitation emitter to the fluorophore.

18. The system of claim 17 , wherein the waveguide comprises an optical fiber.

19. The system of any one of claims 16 to 18, wherein the fluorescence detector comprises a photodiode.

20. The system of any one of claims 16 to 19, wherein the excitation emitter comprises a light emitting diode.

21. The system of any one of claims 16 to 20, further comprising an excitation filter optically coupling the excitation emitter to the fluorophore.

22. The system of any one of claims 16 to 21, further comprising an emission filter that optically couples the fluorophore to the fluorescence detector.

23. The system of claim 15 , wherein the activated sensor comprises a chemical sensor.

24. The system of claim 15 , wherein the activated sensor comprises a plurality of chemical sensors.

25. 25. The system of claim 24, wherein the activated sensor further comprises an excitation emitter operable to emit light at a first wavelength, and the plurality of chemical sensors each comprise a fluorophore configured to emit light at a second wavelength upon receiving light at the first wavelength when the fluorophore is in the presence of an activated photoactivatable agent, and the activated sensor further comprises a fluorescence detector operable to detect the light at the second wavelength emitted by the fluorophore.

26. 26. The system of claim 25, wherein the activated sensor further comprises a plurality of ring resonators operable to filter the light of the second wavelength emitted by the phosphor.

27. 27. The system of claim 25 or 26, wherein the activated sensor further comprises a waveguide optically coupling the excitation emitter to the plurality of chemical sensors.

28. 27. The system of claim 25 or 26, wherein the activated sensor further comprises a waveguide optically coupling the plurality of chemical sensors to the fluorescence detector.

29. 29. The system of claim 27 or 28, wherein the waveguide comprises an optical fiber.

30. 30. The system of any one of claims 15 to 29, wherein the activation sensor is a first activation sensor and further comprises a second activation sensor operable to determine a physiological parameter in the subject, and the controller is further operable to modify the amount of light emitted by the light modulator in response to the second activation sensor determining the physiological parameter in the subject.

Citation Information

Patent Citations

  • Method for adjusting and measuring eccentricity of optical element by use of autocollimator, and method for working lens

    JP2011058872A

  • Compositions and methods for treating pelvic floor neurological disorders

    JP2015509498A

  • Methods, compositions and devices for treating psoriasis by phototherapy

    JP2019511343A

  • Distance measurement device, head-mounted display device, mobile information terminal, video display device, and perimeter monitoring system

    JP6756898B2